Quantcast
Channel: WN.com - Articles related to Actelion to enter Phase II clinical development with new dual orexin receptor antagonist in patients with insomnia (Actelion Ltd)
Viewing all articles
Browse latest Browse all 480

Management Change at Actelion - Roland Haefeli to focus on senior advisory role - Andrew Weiss new Head of Investor Relations and Corporate Communications (Actelion Ltd)

$
0
0
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 05 May 2014 - Actelion Ltd (SIX: ATLN) today announced that Roland Haefeli, Senior Vice President, Head of Investor Relations and Public Affairs (IR & PA) and member of the Extended Actelion Executive Committee (AEC) has decided to step down from his current role for personal reasons effective 05 May 2014. Roland Haefeli will stay with Actelion in a senior advisory role.  Roland will hand over his position to Andrew Weiss, who joins Actelion from Bank Vontobel, where he was Head of Life Science Equity Research / Pharma Analyst. Jean-Paul Clozel M.D. and Chief Executive Officer commented: "I am very pleased to welcome Andrew...

Viewing all articles
Browse latest Browse all 480

Trending Articles



<script src="https://jsc.adskeeper.com/r/s/rssing.com.1596347.js" async> </script>